Opinions Plus
Perspectives on issues affecting biopharma and health care.
Most Read
From the C-Suite: advice on dealing with antsy investors
Rare diseases are losing their immunity in formulary exclusion lists
Inappropriate ‘interchangeability’ requirement for biosimilars will cost the U.S. billions
Talent, culture, and ethics are all necessary ingredients in the biotech recipe for success
In biopharma mergers and acquisitions, managing regulatory compliance early protects return on investment
Why medtech is a different beast than biotech in the life sciences pack
Microbiome drug development: a rapidly evolving field
All Coverage
advertisement
